科研之友
微信
新浪微博
Facebook
分享链接
摘要
Dietary long-chain fatty acid (LCFA) uptake across cell membranes is mediated principally by fatty acid transport proteins (FATP s). Six subtypes of this transporter are differentially expressed throughout the human and rodent body. To facilitate drugs discovery against FATP subtypes, the authors used mammalian cell lines stably expressing the recombinant human FATP 4 and 5 and developed a high-throughput screening (HTS) assay using a 96-well fluorometric imaging plate reader (FLIPR). LCFA uptake signal-to-background ratios were between 3-and 5-fold. Two 4-aryl-dihydropyrimidinones, j3 and j5, produced inhibition of FATP 4 with a half-maximal inhibitory concentration (IC(50)) of 0.21 and 0.63 mu M, respectively, and displayed approximately 100-fold selectivity over FATP 5. The US Drug Collection library was screened against the FATP 5. A hit rate of around 0.4% was observed with a Z' factor of 0.6 +/- 0.2. Two confirmed hits are bile acids, chenodiol and ursodiol with an IC(50) of 2.4 and 0.22 mu M, respectively. To increase throughput, a single time point measurement in a 384-well format was developed using the Analyst HT, and the results are comparable with the 96-well format. In conclusion, the FATP 4 and 5 cell-based fluorescence assays are suitable for a primary drug screen, whereas differentiated cell lines are useful for a secondary drug screen. (Journal of Biomolecular Screening 2010:488-497)
- 出版日期2010-6
